interleukins (IL) and monoclonal antibodies Archives

Abstract Number: 937 • ACR/ARP Annual Meeting 2019
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Lianne Gensler ², Atul Deodhar ³, Xenofon Baraliakos ⁴, Denis Poddubnyy ⁵, Alan Kivitz ⁶, Marga Oortgiesen ⁷, Dominique Baeten ⁸, Nadine Goldammer ⁹, Jason Coarse ⁷, MK Farmer ⁷ and Maxime Dougados ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
Abstract Number: 1482 • ACR/ARP Annual Meeting 2019
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett¹, Xenofon Baraliakos ², Filip Van den Bosch ³, Atul Deodhar ⁴, Lianne Gensler ⁵, Mikkel Østergaard ⁶, Shital Agawane ⁷, Ayan Das Gupta ⁷, Shephard Mpofu ⁸, Todd Fox ⁸, Adam Winseck ⁹, Brian Porter ⁹ and Abhijit Shete ⁸, ¹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Oregon Health & Science University, Portland, OR, ⁵University San Francisco California, San Francisco, CA, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…
Abstract Number: 1597 • ACR/ARHP Annual Meeting 2018
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Jürgen Braun¹, Bjoern Buehring¹, Xenofon Baraliakos¹, Lianne S. Gensler², Brian Porter³, Abhijit Shete⁴, Erhard Quebe-Fehling⁵ and Sibylle Haemmerle⁵, ¹Ruhr-University Bochum, Herne, Germany, ²University of California, San Francisco, CA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Low bone mass is common in ankylosing spondylitis (AS) and patients (pts) with AS have an increased risk of bone fracture.1-3 Treatment of AS…

Abstracts tagged "interleukins (IL) and monoclonal antibodies"

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials

Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study